The LightCycler System is the smartest innovation for more efficient PCR. The LightCycler System enables you to perform rapid PCR in less than 30 min, and simultaneously quantify and analyze the resu
Chemically Resistant Sealing Mat for 384ch, Square Well Available Sterile
Silicone Compression Mat, Bulk
...e Moto Alpha unit, these new pads may be used in a...eral successive runs may be sealed with the same p... a microplate from sticking to the block and lid, ... sealing performance, which means you can use as l...
Medicine Products:(Date:12/3/2008)... Mayo Clinic study found that patients with low-gr...ggressive surgeries to successfully remove the ent... not possible, patients survived significantly lon.... This study is available online as an advance pub...gy.dukejournals.org/cgi/content/abstract/15228517-...
(Date:12/3/2008)...e-USNewswire/ -- The American College of Surgeons ...IOM) for its committee report on resident duty hou...OM Committee on Optimizing Graduate Medical Traine...atient Safety. , , ACS agrees with the IO... mandated 80-hour work week (averaged over four we...
(Date:12/3/2008)...ire/ -- Aurora Health Care,s Women,s Pavilion,( h... Solutions Salon and Spa of,New Berlin partnered ...,cancer; pink hair extensions. , Throughou...being sold for,$15 each at the Aurora Women,s Pav...s Salon and Spa in New Berlin. The profits from th...
(Date:12/3/2008)...Newswire-FirstCall/ -- Forest Laboratories, Inc. (...ified of an unsolicited mini-tender offer by TRC C...vate investment company. Forest Laboratories has ... to 3.0 million outstanding shares of the company,...ent of its outstanding shares. The offer price of...
Breaking Medicine News(10 mins):Health News:Mayo Clinic identifies best treatments for long-term survival in brain tumor patients 2Health News:American College of Surgeons Comments on Institute of Medicine Report on Resident Duty Hours 2Health News:Forest Laboratories Responds To Unsolicited Mini-Tender Offer 2Health News:Forest Laboratories Responds To Unsolicited Mini-Tender Offer 3...eople who are considered obese are significantly m...rding to a recent study . They say that their find...lead to earlier death, even when people are receiv...rtbeat back to normal. Researchers say they have f...
... knee is very common, affecting almost one-tenth o... incurable illness //, so treatment is aimed at im...upuncture was studied. Acupuncture in addition to ...ore effective than drug treatment alone, shows new...
...ed with ultrasound therapy in addition to medicati...to patients only treated with medication, accordin...s who suffered acute ischemic stroke due to a bloc...the patients were treated with tissue plasminogen ...
...haled insulin is effective and well tolerated in p...o provides glycemic control comparable to a conven...pants randomly received either inhaled insulin wit...ections of regular insulin for six months. Hypogly...
Other Medicine News:(Date:12/1/2008)...TargeGen has announced that an oral,presentation ...sed clinical,trial of TG101348 in myeloproliferat...08 American Society of Hematology (ASH) Meeting. ,...ws:, Title: A Phase I Study of ... JAK2-Selective Inhibitor, in Patients with...
(Date:12/1/2008)...-- Roche announced today that a,comparative study...in and,discomfort associated with blood glucose t...systems and lancing devices were deemed least pain... ACCU-CHEK Aviva and ACCU-CHEK Compact,Plus blood...iclix, ACCU-CHEK,Softclix and ACCU-CHEK Softclix ...
(Date:12/1/2008)...e is a two-way switch that, if turned off, causes ...that they lose their identity and become more like..., Dec. 1 Scientists at...ered that a certain differentiated cell type is so... constant expression of a gene called Prox1 to d...
(Date:12/1/2008)...ewswire-FirstCall/ -- Genaera Corporation (Nasdaq... has begun in study MSI-1436C-102 (Study 102), the...uemine (MSI-1436) in overweight and obese type 2 d...treatment of type 2 diabetes and obesity which wor...and leptin pathways through the highly selective i...
Breaking Medicine Technology:Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Physical activity after bariatric surgery improves weight loss quality of life 29950 1Physical activity after bariatric surgery improves weight loss quality of life 29950 2Gaps in adhesion 5896 1Smoking May Harm the Egg Embryo 29947 1Smoking May Harm the Egg Embryo 29947 2Money motivates doctors to reduce ethnic differences in heart disease treatments 29943 1Money motivates doctors to reduce ethnic differences in heart disease treatments 29943 2...w Study Results Show Antibodies Against Cancer-Cau... Times Greater Than Natural,Infection Levels, CHIC...ata show,that at 18 months after the first of a th...5 vaccinated with the GlaxoSmithKline,(GSK) cervic...,against the two most common cancer-causing human ...
...HICAGO, DARMSTADT, Germany, June 5, 2007 – T...logy (ASCO) meeting,in Chicago sees a wealth of pr...quo;s targeted cancer therapy Erbitux®,(cetuxi...y and,versatility of this agent in both first-line... cancer (mCRC) and squamous cell,carcinoma of the ...
Other Medicine Technology:Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 2Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 3Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 4Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 5Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 2Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 3Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 4Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 5Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 6Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 7Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 8